Amygdala Neurofeedback for Depression - Large Scale Clinical Trial

Summary

The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as a stand-alone intervention for major depressive disorder

Eligibility

Inclusion Criteria:

* ages 18 - 55
* primary diagnosis of MDD and are currently depressed
* able to give written informed consent prior to participation
* unmedicated OR are stable on an antidepressant regime (at least 4 weeks to ensure symptoms are stable). Effective medications will not be discontinued for the purposes of the study.

Exclusion Criteria:

* clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder
* Current severe DSM-V alcohol or substance use disorder, with the exception of nicotine or caffeine. Clinician will access subjects' alcohol and substance use on a case-by-case to determine whether specific cases of mild or moderate alcohol or substance use would also interfere with the effects of the intervention.
* history of traumatic brain injury
* unable to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)
* currently pregnant or breast feeding
* unable to complete questionnaires written in English
* current (within 3 weeks of testing) use of any antipsychotics, anticonvulsants, stimulants, benzodiazepines, beta-blockers, or other medications (except antidepressants) likely to influence cerebral blood flow. Effective medications will not be discontinued for the purposes of the study.
* diagnosis of psychotic or organic mental disorder, bipolar I or II disorder.
* eye problems or difficulties in corrected vision.

Conditions2

Locations1 site

Find trials near these locations

Browse More Trials